Joint EANM/SNMMI procedure guideline for the use of &lt;sup&gt;177&lt;/sup&gt;Lu-labeled PSMA-targeted radioligand-therapy (&lt;sup&gt;177&lt;/sup&gt;Lu-PSMA-RLT).

C, Kratochwil; WP, Fendler; M, Eiber; MS, Hofman; L, Emmett; J, Calais; JR, Osborne; A, Iravani; P, Koo; L, Lindenberg; RP, Baum; MF, Bozkurt; Bolton RC, Delgado; S, Ezziddin; F, Forrer; RJ, Hicks; TA, Hope; L, Kabasakal; M, Konijnenberg; K, Kopka; M, Lassmann; FM, Mottaghy; WJG, Oyen; K, Rahbar; H, Schoder; I, Virgolini; L, Bodei; S, Fanti; U, Haberkorn; K, Hermann

doi:10.1007/s00259-023-06255-8

Public

Joint EANM/SNMMI procedure guideline for the use of <sup>177</sup>Lu-labeled PSMA-targeted radioligand-therapy (<sup>177</sup>Lu-PSMA-RLT).

Shared by NobleBlocks on May 29, 2023 • 12:00 AM UTC

Authors:

Kratochwil C

Fendler WP

Eiber M

Abstract

Prostate-specific membrane antigen (PSMA) is expressed by the majority of clinically significant prostate adenocarcinomas, and patients with target-positive disease can easily be identified by PSMA PET imaging. Promising results with PSMA-targeted radiopharmaceutical therapy have already been obtain...

Subject

Psma

[177Lu]lu-psma-617

Eanm/snmmi

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!